Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A 26-year-old Hispanic woman presented to the emergency department (ED) with myalgia and weakness. There were no prior symptoms and family history was negative for endocrinopathies. She was admitted and started on methimazole 10 mg twice a day for thyroid suppression and given propranolol 10 mg twice a day for anticipated hyperadrenergic adverse effects. The remainder of her hospital stay was uneventful and she was discharged 6 days after admission. Soon after, an outpatient thyroid scan ordered by her primary care physician confirmed that the patient had Graves' disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Time to improvement following teprotumumab treatment of thyroid eye disease: real world experience.
Graefes Arch Clin Exp Ophthalmol
August 2025
Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel.
Background: Teprotumumab is the only FDA-approved medication for thyroid eye disease (TED), showing benefits in reducing proptosis, diplopia, clinical activity score (CAS), and improving quality of life. This study describes the clinical outcomes of TED patients treated with Teprotumumab across 5 medical centers in Israel and evaluates time-to-improvement.
Methods: A retrospective cohort study of electronic medical records for Israeli patients treated with Teprotumumab between 2021 and 2024 in five medical centers.
Thyrotoxic periodic paralysis complicated by carbimazole-associated myositis.
BMJ Case Rep
September 2024
Endocrinology, Concord Repatriation General Hospital, Concord, New South Wales, Australia.
A male of East Asian background in his 30s presented to the emergency department with acute onset global muscle weakness, elevated creatine kinase, profound hypokalaemia and hyperthyroidism. A diagnosis of thyrotoxic periodic paralysis was made and the myopathy resolved promptly with potassium replacement. However, 3 months after being commenced on carbimazole for hyperthyroidism, the patient developed myalgias without weakness associated with an elevated creatine kinase.
View Article and Find Full Text PDFNeck Pain and Symptomatic Hypothyroidism: An Atypical Presentation of Subacute Thyroiditis.
Cureus
April 2024
Family Medicine, Christ Health Center, Birmingham, USA.
Subacute thyroiditis (SAT) is a rare form of thyroid disease characterized by fever, neck pain, and dysregulated thyroid hormone levels. It is caused by the post-viral inflammation and destruction of thyroid follicles. Patients typically present with symptoms of hyperthyroidism, as stored thyroid hormone is released into the blood.
View Article and Find Full Text PDFCase 13-2024: A 27-Year-Old Man with Leg Weakness.
N Engl J Med
April 2024
From the Departments of Medicine (A.S.A., N.S.), Radiology (C.L.C.), and Pathology (P.M.S.), Massachusetts General Hospital, and the Departments of Medicine (A.S.A., N.S.), Radiology (C.L.C.), and Pathology (P.M.S.), Harvard Medical School - both in Boston.
Antithyroid Drug-Induced Agranulocytosis: A Case Report.
Cureus
November 2023
Internal Medicine, University of Texas Medical Branch, Galveston, USA.
Agranulocytosis is a rare but life-threatening complication of methimazole and propylthiouracil, antithyroid drugs (ATDs) prescribed for the treatment of hyperthyroidism. We report the case of a 41-year-old female who presented to our institution with complaints of fevers, chills, sore throat, myalgias, and generalized weakness one month after treatment initiation with methimazole. A complete blood count at admission revealed agranulocytosis with an absolute neutrophil count of 0/μl.
View Article and Find Full Text PDF